- New research debunks cardiac safety concerns of Hydroxychloroquine (HCQ) combined with Azithromycin, Vitamin C, Vitamin D, and Zinc.
- Despite the protocol being vilified, the ProgenaBiome study finds no significant cardiac risks in critically ill COVID-19 patients treated with this protocol.
- Utilizing continuous EKG monitoring and statistical analysis, the study concludes that the protocol is a safe and viable option for COVID-19 treatment.
- The research challenges the suppression of alternative COVID-19 treatments, citing controversies and unethical retraction of previous studies on HCQ and Azithromycin.
- Bio-pharmaceutical interests prioritize profit over public health, promoting more expensive mRNA vaccines.
- Study urging stakeholders to prioritize evidence-based policies and accessible treatments.
HCQ, azithromycin, vitamin C & D, and zinc proven safe again
In a stunning revelation that challenges the prevailing narrative on COVID-19 treatments, new research published in the journal BMC Cardiovascular Disorders has definitively debunked concerns over the cardiac safety of Hydroxychloroquine paired with Azithromycin, Vitamin C, Vitamin D, and Zinc (HAZDPac). The ProgenaBiome study, conducted by a team of esteemed researchers including Sabine Hazan, Adriana C. Vidal, Nicolas Hulscher, Amelia Goudzwaard, Peter A. McCullough, and Alon A. Steinberg, provides crucial evidence that this combination therapy does not pose significant cardiac risks.
The present study, a Phase II Double-Blind Randomized Placebo-Controlled Trial, meticulously monitored 83 critically ill COVID-19 patients over a 10-day period. Patients receiving HAZDPac treatment showed no significant prolongation of the QTc interval compared to those on placebo. This finding is particularly significant because concerns over QTc interval prolongation have been a major obstacle in the use of Hydroxychloroquine for COVID-19 treatment.
The research design employed continuous EKG monitoring, enabling the team to gather highly accurate data. Utilizing two-sample t-tests, the researchers analyzed QTc intervals recorded from patients in the treatment group and those on placebo, with no significant differences observed. The study's conclusion is unequivocal: HAZDPac, a potent combination therapy, remains a safe and viable option for treating COVID-19, and its use does not lead to cardiac complications.
The findings are particularly noteworthy in light of the ongoing ethical debates surrounding the suppression of alternative COVID-19 treatments. One such controversial episode involves the retraction of a landmark study on Hydroxychloroquine and Azithromycin published by the same research team. This study had been widely cited by 6,713 scientists and researchers over four years before being unjustly removed from circulation. Such retraction raises serious questions about the integrity of scientific inquiry and the motivations behind such actions.
Bio-pharmaceutical complex conspires to shut down, vilify, and retract studies on helpful treatments for COVID-19
The retraction, dubbed an act of "unethical suppression" by the research community, is seen as part of a broader strategy by biopharmaceutical interests to prioritize profit over public health. "The Biopharmaceutical Complex," as some critics have called it, is accused of systematically downplaying or censoring evidence that might support the use of cheaper, safer, and more accessible treatments like Hydroxychloroquine. The smear campaign against HCQ, for instance, led to publications claiming that HCQ caused 17,000 deaths. This was exposed as fraud. This strategy made way for the promotion of more expensive mRNA vaccines and remdesivir, pushed onto patients under emergency use authorization.
Despite the significant challenges faced, the authors of this study remain steadfast in their commitment to scientific truth and public health. "We will continue to conduct, support, and disseminate high-quality research," stated Professor Peter A. McCullough, a key figure in the research community. "It is our duty to uphold scientific integrity and ensure that effective treatments reach those who need them."
The implications of these findings are profound. Not only do they suggest that hydroxychloroquine is safe for outpatient use, but they also challenge the market dynamics that have governed the response to the pandemic. If Hydroxychloroquine proves to be an effective and accessible treatment, the implications for global health policies and the affordability of care could be profound.
As the research community continues to grapple with ethical and scientific challenges in the wake of the pandemic, the ProgenaBiome study stands as a powerful testament to the resilience of scientific inquiry and the undying commitment to truth and public welfare. It is a call to action for all stakeholders to reevaluate their priorities and ensure that the search for effective treatments is driven by evidence, not by the dictates of commercial interests.
Sources include:
PeterMcCulloughMD.substack.com
PeterMcCulloughMD.substack.com
Please contact us for more information.